Implementation of a gene therapy education initiative by the ASGCT and Muhimbili University of Health and Allied Sciences
- PMID: 37595584
- PMCID: PMC10492022
- DOI: 10.1016/j.ymthe.2023.07.019
Implementation of a gene therapy education initiative by the ASGCT and Muhimbili University of Health and Allied Sciences
Abstract
There has been rapid growth in gene therapy development with an expanding list of approved clinical products. Several therapies are particularly relevant to patients in low- and middle-income countries. Moreover, investing in research and manufacturing presents an opportunity for economic development. To increase awareness of gene therapy, the American Society of Gene and Cell Therapy partnered with the Muhimbili University of Health and Allied Sciences, Tanzania, to create a certificate-bearing course. The goal was to provide faculty teaching in graduate and medical schools with the tools needed to add gene therapy to the university curriculum. The first virtual course was held in October of 2022, and 45 individuals from 9 countries in Africa completed the training. The content was new to approximately two-thirds of participants, with the remaining third indicating that the course increased their knowledge base. The program was well received and will be adapted for other under-resourced regions.
Copyright © 2023 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.
Figures


References
-
- Rosenberg S.A., Aebersold P., Cornetta K., Kasid A., Morgan R.A., Moen R., Karson E.M., Lotze M.T., Yang J.C., Topalian S.L., et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 1990;323:570–578. - PubMed
-
- Forum W.E. Accelerating Global Access to Gene Therapies: Case Studies from Low- and Middle-Income Countries. World Econ. Forum. 2022 https://www.weforum.org/whitepapers/accelerating-global-access-to-gene-t...
-
- MIT NEWSDIGS Research Brief Updated projection of US durable cell and gene therapies product-indication approvals based on December 2019 development pipeline. Mass. Inst. Technol. FoCUS. 2020 https://newdigs.mit.edu/sites/default/files/NEWDIGS-Research-Brief-2020F...
-
- Richardson M., Rind D., Beaudoin F.L., Pearson S.D., Campbell J.D. The Fair Price For One-Time Treatments; How Can We Overcome Existing Market Price Distortions? HealthAffairs. 2023 doi: 10.1377/forefront.20230117.20110613. - DOI
-
- Senior M. After Glybera’s withdrawal, what’s next for gene therapy? Nat. Biotechnol. 2017;35:491–492. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical